Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

1. A glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene compound according to general formula I

wherein

R 1 denotes hydrogen, fluorine, chlorine, bromine, iodine, C 1-4 -alkyl, C 2-6 -alkynyl, C 1-4 -alkoxy, C 2-4 -alkenyl-C 1-4 -alkoxy, C 2-4 -alkynyl-C 1-4 -alkoxy, methyl substituted by 1 to 3 fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5 fluorine atoms, C 1-4 -alkyl substituted by a hydroxy or C 1-3 -alkoxy group, C 2-4 -alkoxy substituted by a hydroxy or C 1-3 -alkoxy group, C 2-6 -alkenyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-3 -alkyl, C 3-7 -cycloalkyloxy, C 3-7 -cycloalkyl-C 1-3 -alkoxy, C 5-7 -cycloalkenyloxy, hydroxy, amino, nitro or cyano, while in the C 5-6 -cycloalkyl groups a methylene group may be replaced by O;

R 2 denotes hydrogen, fluorine, chlorine, bromine, hydroxy, C 1-4 -alkyl, C 1-4 -alkoxy, cyano or nitro, while the alkyl or alkoxy group may be mono- or polysubstituted by fluorine, and

R 3 denotes an aryl-group or a 5- or 6-membered monocyclic heteroaryl-group or a 8-, 9- or 10-membered bicyclic heteroaryl-group wherein said heteroaryl-groups have 1 to 4 heteroatoms independently selected from the group consisting of N, O and S; and

wherein said heteroaryl-group may possess 1 or 2 carbonyl groups as part of the mono- or bicyclic aromatic ring-system; and

wherein an N-atom of the heteroaryl ring-system may be oxidized to form the corresponding N-oxide; and

wherein one or more methine groups in said aryl- and heteroaryl-group may be substituted independently of one another with a substituent L1; and

wherein one or more imino-groups in said heteroaryl-group may be substituted independently of one another with a substituent R N ; and

R 4 , R 5 independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, C 1-3 -alkyl, C 1-3 -alkoxy or a methyl- or methoxy-group substituted by 1 to 3 fluorine atoms,

L1 independently of one another are selected from among fluorine, chlorine, bromine, iodine, hydroxy, cyano, C 1-3 -alkyl, difluoromethyl, trifluoromethyl, C 1-3 -alkoxy, difluoromethoxy, trifluoromethoxy, amino, C 1-3 -alkyl-amino and di(C 1-3 -alkyl)-amino; and

R N independently of one another are selected from among C 1-3 -alkyl; and

R 6 , R 7a ,

R 7b , R 7c independently of one another have a meaning selected from among hydrogen, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, while the aryl-groups may be mono- or disubstituted independently of one another by identical or different groups L1;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be substituted as defined; and

while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched,

the tautomers, the stereoisomers, mixtures and salts thereof.

2. A glucopyranosyl-substituted (hetero)arylethynyl-benzene derivative of general formula I.2

wherein the groups R 1 to R 6 and R 7a , R 7b and R 7c are defined as in claim 1 .

3. A glucopyranosyl-substituted (hetero)arylethynyl-benzene compound according to claim 1 , characterised in that the group R 3 is an aryl-group or a 5- or 6-membered monocyclic heteroaryl-group wherein the term 5- or 6-membered monocyclic heteroaryl-group denotes a pyrrolyl, furanyl, thienyl, pyridyl or tetrazolyl group, or

a pyrrolyl, furanyl, thienyl or pyridyl group wherein one or two methine groups are replaced in each case by a nitrogen atom,

wherein said heteroaryl-groups optionally possess 1 or 2 carbonyl groups as part of the aromatic ring-system;

wherein an N-atom of the heteroaryl ring-system may be optionally oxidized to form the corresponding N-oxide; and

wherein one or more methine-groups in said phenyl or said heteroaryl-groups may be optionally substituted independently of one another with a substituent L1; and

wherein one or more imino-groups in said heteroaryl-groups may be optionally substituted independently of one another with a substituent R N ;

wherein L1 and R N are defined as in claim 1 .

4. A glucopyranosyl-substituted (hetero)arylethynyl-benzene compound according to one or more of claim 1 , characterised in that the group R 1 denotes hydrogen, fluorine, chlorine, bromine, C 1-4 -alkyl, C 1-4 -alkoxy, methyl substituted by 1 to 3 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, C 3-7 -cycloalkyloxy or C 3-7 -cycloalkyl-C 1-3 -alkoxy, while in the C 5-6 -cycloalkyl groups a methylene group may be replaced by O.

5. A glucopyranosyl-substituted benzene compound according to one claim 1 , characterised in that the group R 2 denotes hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy and methyl substituted by 1 to 3 fluorine atoms.

6. A glucopyranosyl-substituted benzene compound according to claim 1 , characterised in that the groups R 4 and/or R 5 independently of one another represent hydrogen or fluorine.

7. A glucopyranosyl-substituted benzene compound according to claim 1 , characterised in that the group R 6 denotes hydrogen, (C 1-8 -alkyl)oxycarbonyl, C 1-8 -alkylcarbonyl or benzoyl, preferably hydrogen.

8. A glucopyranosyl-substituted benzene compound according to claim 1 , characterised in that the groups R 7a , R 7b , R 7c represent hydrogen.

9. A physiologically acceptable salt of any of the compounds according to claim 1 with inorganic or organic acids.

10. A pharmaceutical composition, comprised of a compound according to claim 1 or a physiologically acceptable salt with organic or inorganic acids optionally together with one or more inert carriers and/or diluents.

11. A method of treating diseases or conditions which can be influenced by inhibiting the sodium-dependent glucose transporter SGLT, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.

12. A method for inhibiting the sodium-dependent glucose cotransporter SGLT2, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof.

13. A method of treating the degeneration of pancreatic beta cells and/or restoring the functionality of pancreatic cells, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof.

14. A process for preparing a compound of general formula I according to claim 1 , comprised of the steps of reacting a compound of general formula II

wherein

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b ,

R 8c , R 8d independently of one another have one of the meanings given for the groups R 7a , R 7b , R 7c , denote a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 and R 6 , R 7a , R 7b , R 7c have the meanings given in claim 1 ,

with a reducing agent in the presence of a Lewis or Brønsted acid, and cleaving protective groups present simultaneously or subsequently;

optionally converting a compound of general formula I thus obtained wherein R 6 denotes a hydrogen atom, into a corresponding acyl compound of general formula I, and/or;

optionally cleaving any protective group used in the reactions described above

optionally resolving a compound of general formula I thus obtained into its stereoisomers and/or

optionally converting a compound of general formula I thus obtained into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.

15. A process according to claim 14 , wherein the compound of general formula II is made by:

wherein

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b ,

R 8c , R 8d independently of one another have one of the meanings given for the groups R 6 , R 7a , R 7b , R 7c , denote a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 and R 3 , R 7a , R 7b , R 7c

wherein an organometallic compound (V) which may be obtained by halogen-metal exchange or by the insertion of a metal in the carbon-halogen bond of a halogen-benzylbenzene compound of general formula IV

wherein Hal denotes Cl, Br and I and R 1 to R 5 are as hereinbefore defined, and optionally subsequent transmetallation, is added to a gluconolactone of general formula VI

wherein R 8a , R 8b , R 8c , R 8d are as hereinbefore defined,

and

then the resulting adduct is reacted with water or an alcohol R′—OH, where R′ denotes optionally substituted C 1-4 -alkyl, in the presence of an acid and optionally the product obtained in the reaction with water wherein R′ denotes H is converted in a subsequent reaction with an acylating agent into the product of formula II wherein R′ denotes (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl or aryl-(C 1-3 -alkyl)-carbonyl, which may be substituted as specified.

16. A process according to claim 15 , wherein the organometallic compound (V) is a lithium or magnesium compound.

17. A process for preparing the compounds of general formula I according to claim 1 , wherein R 6 , R 7a , R 7b and R 7c represent hydrogen comprised of the step of hydrolyzing a compound of general formula III

wherein

R 8a , R 8b ,

R 8c , R 8d independently of one another have one of the meanings given for the groups R 6 , R 7a , R 7b , R 7c , but at least one of the groups R 8a , R 8b , R 8c , R 8d does not denote hydrogen, or denotes a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms a substituted dioxane ring together with two oxygen atoms and the associated two carbon atoms of the pyranose ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another represent C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 , R 6 , R 7a , R 7b , R 7c have the meanings given in claims 1 to 8 ,

and

optionally converting a compound of general formula I thus obtained wherein R 6 denotes a hydrogen atom is converted by acylation into a corresponding acyl compound of general formula I, and/or

optionally cleaving any protective group used in the reactions described above

optionally resolving a compound of general formula I thus obtained is into its stereoisomers and/or

optionally converting a compound of general formula I thus obtained is into the salts thereof.

18. A process according to claim 17 , where in the compound of general formula I is comprised of the steps of reacting a compound of general formula II

wherein

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b ,

R 8c , R 8d independently of one another have one of the meanings given for the groups R 7a , R 7b , R 7c , denote a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 and R 6 , R 7a , R 7b , R 7c have the meanings given in claim 1 ,

with a reducing agent in the presence of a Lewis or Brønsted acid, and cleaving protective groups present simultaneously or subsequently;

optionally converting a compound of general formula I thus obtained wherein R 6 denotes a hydrogen atom, into a corresponding acyl compound of general formula I, and/or

optionally cleaving any protective group used in the reactions described above

optionally resolving a compound of general formula I thus obtained into its stereoisomers and/or

optionally converting a compound of general formula I thus obtained into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.

19. A compound of general formula IV

wherein Hal denotes chlorine, bromine or iodine and the groups R 1 , R 2 , Rt 3 , R 4 and R 5 are defined as in claim 1 .

20. Compound of formula IV according to claim 19 , characterised by the formula

wherein Hal denotes chlorine, bromine or iodine.

21. A compound of general formula II

wherein

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl and aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b ,

R 8c , R 8d independently of one another have one of the meanings given for the groups, R 6 , R 7a , R 7b , R 7c , or denote a benzyl group or a R a R b R c Si group or a ketal or acetal group, while in each case two adjacent groups R 8a R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R 1 to R 5 are defined as in claim 1 .